2024 Asia Conference on Lung Cancer (ACLC) - Poster & ePosters-PP02.07

PP02.07 - Heng Yao

Pdf Summary

The retrospective analysis investigates the efficacy of neoadjuvant ALK inhibitor treatment in patients with resectable ALK-positive non-small cell lung cancer (NSCLC). ALK-positive NSCLC forms a distinct subset of the disease with specific therapeutic targets, and prior studies have shown significant efficacy of ALK inhibitors in advanced stages. This analysis explores their potential role in pre-surgical settings to improve surgical outcomes.<br /><br />The study examined nine patients with confirmed ALK-positive lung adenocarcinoma who received neoadjuvant ALK tyrosine kinase inhibitors (TKIs) before surgical resection. The duration of therapy varied significantly, with a median treatment period of 180 days. The primary endpoints focused on pathological response rates, and secondary endpoints evaluated safety and tolerability.<br /><br />Results demonstrated promising outcomes, with all patients exhibiting partial radiological responses and tumor size reductions, varying from 42% to 80%. Notably, 55.6% of the patients achieved a complete pathological response with no viable tumor cells in the resected specimens. The therapy was well-tolerated with no severe postoperative complications directly linked to the neoadjuvant treatment. Moreover, over a median follow-up of 22 months, patients showed no local recurrence or distant metastasis, suggesting a potentially encouraging disease-free survival rate post-treatment.<br /><br />Despite favorable responses, the study acknowledges limitations due to its small sample size and retrospective design. These findings advocate for future prospective studies with larger cohorts to confirm the role of neoadjuvant ALK inhibitors in managing ALK-positive NSCLC effectively.<br /><br />This research underscores the potential benefits of utilizing neoadjuvant ALK inhibitors in enhancing pathological response and disease-free survival in ALK-positive NSCLC patients, thereby suggesting a promising avenue for improving treatment protocols in this patient subset.

Keywords

neoadjuvant ALK inhibitor

ALK-positive NSCLC

non-small cell lung cancer

pathological response

disease-free survival

ALK tyrosine kinase inhibitors

tumor size reduction

surgical outcomes

retrospective analysis

therapeutic targets